evolution of autosct in multiple myeloma: patient demographics and improved outcomes
Published 6 months ago • 90 plays • Length 3:50Download video MP4
Download video MP3
Similar videos
-
4:17
the evolving role of autosct in the age of car-t for multiple myeloma: current & future perspectives
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
2:19
disease staging systems in multiple myeloma and how these have evolved over the years
-
2:00
real-world outcomes of autosct for multiple myeloma in the first-line setting
-
1:48
the role of autologous transplantation in young and fit patients with multiple myeloma in 2022
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:10
what is multiple myeloma? - animated
-
2:53
myeloma uk clonal evolution in myeloma
-
0:59
defining the origins of multiple myeloma
-
5:20
the evolution of clonal hematopoiesis and associated outcomes in multiple myeloma
-
1:30
exploring the role of upfront autosct in multiple myeloma
-
1:33
the role of allogeneic transplantation in patients with multiple myeloma
-
1:29
the future of adcs in treating multiple myeloma
-
1:53
transplantation for consolidation in multiple myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
2:22
the benefit of autologous transplantation in the era of novel agents in multiple myeloma
-
3:00
current & emerging biomarkers in multiple myeloma
-
4:00
optimizing the outcomes of autohsct in multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
2:10
the evolution of the myeloma treatment landscape
-
1:16
the evolving use of selinexor in multiple myeloma
-
2:30
a new era of treatment for multiple myeloma